Carmell Therapeutics Announces Appointment of Dr. Israel Nur as Scientific Advisor
PITTSBURGH--(BUSINESS WIRE)--Oct 7, 2020--
Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Dr. Israel Nur joined the company as a Scientific Advisor. Carmell Therapeutics has a unique biologic solution that addresses unmet needs in bone and soft tissue treatment and utilizes an innovative, proprietary platform that accelerates healing, reduces complications and enables patients to get back to their daily lives more quickly.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005097/en/
Israel Nur joins Carmell Therapeutics as Scientific Advisor (Photo: Business Wire)
“Israel brings a wealth of plasma derivatives experience and will provide invaluable guidance to Carmell as we continue to expand, which we are doing across the board, in fact, we’ve already doubled our footprint in Pittsburgh,” said Randy Hubbell, President and Chief Executive at Carmell Therapeutics. “We are thrilled to welcome Israel at this pivotal time for the organization as we advance our efforts to bring CT-101 Bone Healing Accelerant (BHA) to patients and healthcare providers.”
Earlier this year, Carmell received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its BHA, which will help expedite the company’s lead program to the goal of a Biologic License Application (BLA) approval.
“I’m looking forward to working with Carmell at this exciting time and sharing my expertise in biologic development of plasma-based materials,” said Dr. Israel Nur. “Bone Healing Acceleration is an important area that could make a considerable impact in the orthopedic/wound healing market and Carmell has the unique, transformational technology to make this a reality.”
Dr. Israel Nur has over four decades of research and development (R&D) in biological experience, with a strong focus in plasma and serum derived product industry, in both the public and private sectors. He has proven expertise in developing biosurgical combination products. Most recently, Israel Nur was a senior director at Ethicon, leading the Manufacturing Scientific Team. Before that, he was managing the Ethicon Biosurgery R&D research and innovation team. Prior to the acquisition of Omrix biopharmaceuticals Inc. by JNJ, Dr. Nur was VP, R&D and one of the founders of Omrix. He also developed a line of plasma derived products, including the Intravenous immunoglobulin (OmriGam). During the early 2000s, under his leadership and with the collaboration of the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Israel Defense Forces (IDF), the US Army and the Ministry of Defense, Omrix developed and manufactured a line of biodefense and bioterrorism products. Before joining the industry, Dr. Nur was a Visiting Fellow, Laboratory of Biochemical Pharmacology, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, in Bethesda, Maryland. He started his career in NIH as a research fellow in National Institute of Allergy and Infectious Diseases (NIAID) in Fort Dietrich, Frederick MD.
Dr. Nur is an author of 53 publications in peer review journals and an inventor of more than 40 patents. He earned a Doctor of Philosophy in Biochemistry and a Master of Science in Microbiology from The Hebrew University of Jerusalem in Israel.
About Carmell’s PBM Technology Platform
Carmell Therapeutics’ unique PBM technology platform can be delivered in multiple formats to the site of injury – from putties to pastes to surgical screws. A proprietary manufacturing process ensures product safety and that bioactive regenerative factors are delivered as the product degrades allowing for optimal healing. Carmell® currently has two PBM products in development – a Bone Healing Accelerant and a Tissue Healing Accelerant.
About Carmell Therapeutics
Carmell Therapeutics (Carmell) is addressing the burden of bone and tissue healing with its proprietary Plasma-based Bioactive Material (PBM) technology, designed to improve patient outcomes and reduce health care costs. Carmell’s transformational biologic will have significant impact on important therapeutic areas with many unmet clinical needs such as trauma fixation healing, spine fusion, sports medicine, dental bone regrowth, wound care, aesthetic medicine and animal health. For more information, please visit www.carmellrx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201007005097/en/
CONTACT: Randy Hubbell
KEYWORD: UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST PENNSYLVANIA
INDUSTRY KEYWORD: RESEARCH PHARMACEUTICAL MEDICAL DEVICES CLINICAL TRIALS SCIENCE SURGERY BIOTECHNOLOGY STEM CELLS MEDICAL SUPPLIES FDA OTHER SCIENCE HEALTH
SOURCE: Carmell Therapeutics
Copyright Business Wire 2020.
PUB: 10/07/2020 08:24 AM/DISC: 10/07/2020 08:24 AM